BIVI

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Wall Street analysts forecast BIVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIVI is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioVie Inc revenue for the last quarter amounts to -5.28M USD, increased 41.98 % YoY.

BioVie Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

BioVie Inc (BIVI) has 13 emplpoyees as of December 17 2025.

Today BIVI has the market capitalization of 10.78M USD.